Basic Information
ROCKLATAN OPHTHALMIC SOLUTION, 0.02% W/V / 0.005% W/V
SOLUTION, STERILE
Regulatory Information
SIN16818P
July 4, 2023
Prescription Only
Therapeutic
OPHTHALMIC
August 10, 2023
May 30, 2025
XS01EE51
Company Information
SANTEN PHARMACEUTICAL ASIA PTE. LTD.
SANTEN PHARMACEUTICAL ASIA PTE. LTD.
Active Ingredients
Strength: 0.005% w/v
Strength: 0.02% w/v
Detailed Information
Contraindications
**4\. CONTRAINDICATIONS** Hypersensitivity to the active substance(s) or to any of the excipients.
Indication Information
**1\. INDICATIONS AND USAGE** ROCKLATAN (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is a fixed dose combination of a Rho kinase inhibitor and a prostaglandin F2α analogue indicated for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin F2α analogue or Rho kinase inhibitor provides insufficient IOP reduction.